INI-822
Severe Liver Diseases (MASH)
Phase 1Active
Key Facts
About Inipharm
Inipharm is a private, clinical-stage biotech based in Seattle, advancing a pipeline centered on inhibiting HSD17B13, a target with strong human genetic validation for liver disease. Its lead candidate, INI-822, is a first-in-class small molecule inhibitor currently in Phase 1 trials, including cohorts with MASH (Metabolic dysfunction-Associated Steatohepatitis) patients. The company is led by a seasoned team with deep experience in liver disease drug development and biotech entrepreneurship, aiming to address significant unmet needs in fibrotic liver diseases.
View full company profile